Huber François, Lang Hans Peter, Marten Andrea, Bielicki Julia Anna, Meyer Ernst, Gerber Christoph
Swiss Nanoscience Institute (SNI), Department of Physics, University of Basel, CH-4056 Basel, Switzerland.
University Children's Hospital Basel (UKBB), Department of Medicine, University of Basel, CH-4056 Basel, Switzerland.
Biosensors (Basel). 2025 Mar 28;15(4):217. doi: 10.3390/bios15040217.
Recent advancements in nanomechanical microcantilever biosensors open new possibilities for clinical applications, permitting precise analysis of molecular interactions. The technology enables tracking gene expression, molecular conformational changes, antibody binding and antibiotic resistance. In particular, hybridization of DNA or RNA extracted from biopsies and whole blood from patients has led to significant advancements in diagnostics of critical medical conditions, e.g., cancer, bacteraemia and sepsis, utilizing rapid, sensitive, and label-free detection. Direct diagnosis from patient samples is a decisive advantage over competitive methods circumventing elaborate and time-consuming purification, amplification and cultivation procedures prior to analysis. Here, recent developments are presented from simple DNA hybridization of synthesized oligonucleotides to RNA material obtained from patients' blood samples, highlighting technological advancements in diagnostic applications, such as detection of pathogens and disease biomarkers. We envisage our method to be a significant input to rapid, early and sensitive diagnosis directly from patients' blood without requirements for amplification or cultivation. This would represent a paradigm shift in diagnostics, as no competing method currently exists.
纳米机械微悬臂生物传感器的最新进展为临床应用开辟了新的可能性,能够对分子相互作用进行精确分析。该技术可实现对基因表达、分子构象变化、抗体结合和抗生素耐药性的追踪。特别是,从活检组织和患者全血中提取的DNA或RNA的杂交技术,利用快速、灵敏且无需标记的检测方法,在重大疾病(如癌症、菌血症和败血症)的诊断方面取得了显著进展。与那些在分析前需要进行复杂且耗时的纯化、扩增和培养程序的竞争方法相比,直接从患者样本进行诊断具有决定性优势。在此,本文展示了从合成寡核苷酸的简单DNA杂交到从患者血样中获取的RNA材料的最新进展,突出了诊断应用中的技术进步,如病原体和疾病生物标志物的检测。我们设想我们的方法将为直接从患者血液中进行快速、早期和灵敏的诊断提供重要支持,而无需进行扩增或培养。这将代表诊断领域的范式转变,因为目前尚无与之竞争的方法。